Australia markets open in 5 hours 34 minutes

SAVA Jan 2025 25.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
6.800.00 (0.00%)
As of 10:13AM EDT. Market open.
Full screen
Previous close6.80
Open6.80
Bid6.80
Ask7.75
Strike25.00
Expiry date2025-01-17
Day's range6.80 - 6.80
Contract rangeN/A
Volume1
Open interest395
  • Zacks

    Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross

    When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

  • GlobeNewswire

    Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

    $126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 mill

  • GlobeNewswire

    Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

    Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per ShareAUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distributed to its shareholders (the “Warrants”). Gross proceeds from the Warrants represents the issuance of